CSL Behring
Also known as: CSL Behring | CSL Behring AG | CSL Behring - Director, Medical Affairs Cardiovascular | CSL Behring GmbH | CSL Behring K.K. | CSL Behring Lengnau AG | CSL Behring LLC | CSL BEHRING LLC | CSL Innovation Pty Ltd | CSL Limited | CSL Plasma | Joshua S. Jacobs, MD | Seqirus | Seqirus Inc. | Seqirus Pty Ltd. | Seqirus Vaccines Limited
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2004First marketed drug
Jan 1, 2004First NDA
Jan 20, 2009Last known activity
Nov 15, 2025
Timeline
1970s
- Jul 23, 1976
albumin (Human)— NDA Secondary Org
2000s
- Jan 1, 2004
CSL Behring— Founded
- Jan 1, 2004
CSL— Acquired
- Jan 1, 2004
Zentrallaboratorium Blutspendedienst— Acquired
- Jan 1, 2006
Zenyth Therapeutics— Acquired
2010s
- Mar 4, 2016
factor ix albumin fusion protein— NDA Organization
- Aug 28, 2017
Calimmune, Inc.— Acquired
2020s
- Jun 8, 2020
Vitaeris— Acquired
- Dec 14, 2021
Vifor Inc.— Acquired - Jun 16, 2025
garadacimab— Marketing Organization
Drugs by trial phase (105 distinct, 287 trials)
Phase 4 (12 own, 12 via acquisition)
- C1 Esterase Inhibitor (Human)
- icosapent ethyl
- ferrous fumarate
- iron
- sodium chloride
- alpha-1 antitrypsin
- ferric carboxymaltose
- garadacimab
- epoetin
- fibrinogen (human)
- blood plasma
- ferric sulfate
- immune globulin (human)
- human factor ix complex (prothrombin complex concentrate)
- cytomegalovirus immune globulin intravenous (human)
- +9 more
Phase 3 (19 own, 24 via acquisition)
Phase 2 (12 own, 4 via acquisition)
Phase 1 (12 own, 7 via acquisition)
Other trials (2 own, 1 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Afibrinogenemia
- Agammaglobulinemia
- alpha 1-Antitrypsin Deficiency
- Anemia, Sickle Cell
- Aneurysm
- Angioedema
- Angioedemas, Hereditary
- Aortic Aneurysm
- Aortic Aneurysm, Abdominal
- Aortic Valve Stenosis
- Asthma
- Autoimmune Diseases
- Blood Coagulation Disorders
- Blood Loss, Surgical
- Blood Platelet Disorders
- Bone Marrow Diseases
- Bronchiectasis
- Cerebral Infarction
- Common Variable Immunodeficiency
- Communicable Diseases
- Constriction, Pathologic
- Coronary Artery Disease
- Coronavirus Infections
- Cystic Fibrosis
- Cytomegalovirus Infections
- Dermatomyositis
- Diabetic Nephropathies
- Disease
- Emphysema
- Encephalitis
- Factor VII Deficiency
- Factor XIII Deficiency
- Fasciitis
- Fasciitis, Necrotizing
- Fibrosis
- Fournier Gangrene
- Gangrene
- Gas Gangrene
- Graft vs Host Disease
- Heart Diseases
- Heart Failure
- Heart Valve Diseases
- Hematologic Diseases
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Hemostatic Disorders
- Hereditary Angioedema Types I and II
- Hidradenitis
- Hidradenitis Suppurativa
- IgG Deficiency
- Immunologic Deficiency Syndromes
- Infarction
- Infections
- Inflammation
- Influenza, Human
- Influenza in Birds
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Diseases, Obstructive
- Lymphoma
- Muscle Weakness
- Myasthenia Gravis
- Myocardial Infarction
- Neuritis
- Pneumonia
- Polyneuropathies
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Postoperative Hemorrhage
- Postpartum Hemorrhage
- Psoriasis
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Emphysema
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Renal Insufficiency
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Sinusitis
- Soft Tissue Infections
- Spinal Cord Diseases
- Stroke
- Syndrome
- Thrombosis
- von Willebrand Diseases
- Wounds and Injuries
Marketed drugs (16)
- C1 Esterase Inhibitor (Human)
- alpha-1 antitrypsin
- albumin (Human)
- fibrinogen (human)
- human factor ix complex (prothrombin complex concentrate)
- factor ix albumin fusion protein
- immune globulin (human)
- von Willebrand factor
- inactivated influenza vaccine
- Rho(D) Immune Globulin Intravenous (Human)
- human coagulation factor ix
- antihemophilic factor viii human
- factor xiii concentrate (human)
- antihemophilic factor viii (Recombinant), single chain
- etranacogene dezaparvovec
- garadacimab
Subsidiaries (6 direct, 12 total across the full acquisition tree)
Recent trials (50)
- NCT07159464Lead sponsorN/A—
- NCT07224360Lead sponsorPhase 2Nov 15, 2025
- NCT07224360OfficialPhase 2Nov 15, 2025
- NCT07094087Lead sponsorPhase 3Sep 10, 2025
- NCT07094087OfficialPhase 3Sep 10, 2025
- NCT07048262Lead sponsorPhase 2Sep 3, 2025
- NCT07048262OfficialPhase 2Sep 3, 2025
- NCT07080905Lead sponsorPhase 3Jul 28, 2025
- NCT07080905OfficialPhase 3Jul 28, 2025
- NCT07076446OfficialPhase 4Jul 15, 2025
- NCT07076446Lead sponsorPhase 4Jul 15, 2025
- NCT06996184OfficialPhase 1May 27, 2025
- NCT06996184Lead sponsorPhase 1May 27, 2025
- NCT06806657Lead sponsorPhase 4Mar 14, 2025
- NCT06806657OfficialPhase 4Mar 14, 2025
Details
- Founded
- King of Prussia, PA, US Jan 1, 2004
- First NDA
- Jan 20, 2009
- Last known activity
- Nov 15, 2025
Designations held
- Orphan drug
- Breakthrough therapy
- Accelerated approval